Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-26 @ 10:20 PM
Ignite Modification Date:
2025-12-26 @ 10:20 PM
NCT ID:
NCT07178912
Brief Summary:
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Detailed Description:
Primary Objective
• To evaluate the rate of complete molecular response (CMR; undetectable BCR::ABL1 transcript by RT-PCR) in participants with newly diagnosed Ph-positive ALL and the overall response rate (complete remission + complete remission with incomplete count recovery) in participants with relapsed/refractory Ph-positive ALL
Secondary Objectives
* To evaluate event-free survival (EFS)
* To evaluate overall survival (OS)
* To evaluate MRD negativity by next-generation sequencing (NGS) at a sensitivity of 1x10-6
* To assess the safety of the regimen
Study:
NCT07178912
Study Brief:
Protocol Section:
NCT07178912